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Abstract
Background: Twenty years after the nuclear accident in Chernobyl (Eastern Europe), there is still
a controversial debate concerning a possible effect of the radioactive iodines, especially I-131, on
the increase of thyroid carcinomas (TCs) in Western Europe. Time trends in incidence rates of TC
in Luxembourg in comparison with other European countries and its descriptive epidemiology
were investigated.
Methods: The population-based data of the national Morphologic Tumour Registry collecting new
thyroid cancers diagnosed between 1983 and 1999 at a nation-wide level in the central division of
pathology were reviewed and focused on incidence rates of TC. Data from 1990 to 1999 were used
to evaluate the distribution by gender, age, histological type, tumour size and the outcome.
Results: Out of 310 new thyroid carcinomas diagnosed between 1990 and 1999, 304 differentiated
carcinomas (A: 80% papillary; B: 14.5% follicular; C: 3.5% medullary) and 6 anaplastic/
undifferentiated TCs (D: 2%) were evaluated. The M/F-ratio was 1:3.2, the mean age 48.3 years
(range: 13–92). The overall age-standardized (world population) incidence rates over the two 5-
year periods 1990–1994 and 1995–1999 increased from 7.4 per 100,000 to 10.1 per 100,000 in
females, from 2.3 per 100,000 to 3.6 per 100,000 in males. Only 3 patients were children or
adolescents (1%), the majority of the patients (50%) were between 45 and 69 years of age. The
percentage of microcarcinomas (<1 cm) was A: 46.4%, (115/248); B: 13.3%, (6/45); C: 27.3%, (3/
11). The unexpected increase of TCs in 1997 was mainly due to the rise in the number of
microcarcinomas. The observed 5-year survival rates for both genders were A: 96.0+/-2%; B:
88.9%; C: 90.9%; D: 0%. Prognosis was good in younger patients, worse in males and elderly, and
extremely poor for undifferentiated TCs.
Conclusion: The increasing incidence rates of TC, especially of the papillary type, seem mainly due
to a rise in diagnosed microcarcinomas due to some extent to a change in histologic criteria and
to more efficient diagnostic tools. This rise appears to be independent of the number of surgical
treatments, the immigration rate, and the Chernobyl fallout as the incidence of TC in children
remained stable.
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Background
Since April 1986, the day of the nuclear accident in Cher-
nobyl (Ukraine) leading to the exposure of large popula-
tions to radioactive iodines (particularly I-131) in many
Eastern European countries and to a lesser degree in Cen-
tral and Western Europe, there has been an increased
interest of the health care authorities to collect epidemio-
logical data on cancer incidence, especially in leukaemia
and thyroid cancer (TC) [1,2].
The study aim was to examine time trends (1983–1997)
in the thyroid cancer age-standardized (world popula-
tion) incidence rates in the Grand-Duchy of Luxembourg
(Western Europe), an iodine deficient goitre endemic
area, and to analyse the distribution of TC (1990–1999)
by age, gender, histological type, tumour size, immigra-
tion rate and outcome.
One goal was to present the data on frequency of thyroid
cancers in a goitre endemic area over a ten-year period,
1990–1999, and to identify recent changes, if any. Our
objective was to assess whether these changes could be
artefactual due a) to incorrect or changing histological
diagnoses, b) to more complete case reporting in the post-
Chernobyl era or c) to increased surgical interventions in
individuals with an enlarged, diffuse or nodular pattern
like thyroid gland in the years following the nuclear acci-
dent.
Methods
The design of the study was a retrospective chart review
from 1 January 1983 to 31 December 1999. The descrip-
tive epidemiologic data of thyroid cancer in a selected
area, the Grand-Duchy of Luxembourg, were provided by
the national Morphologic Tumour Registry (MTR), which
is the population-based cancer registry at national level
which collects data on about 95% of the precancerous and
cancerous lesions verified by microscopic examinations.
These thyroid cancer cases had been exclusively diagnosed
and "double-read" in the central division of pathology by
nine senior pathologists. Over the last decade, the 1990s,
the population at risk rose from 384,400 to 435,700, an
average of 1.3 % per year [3]. Patients of all nationalities,
races or ethnic origins living in Luxembourg and treated
for thyroid cancer by surgery were considered. Disease his-
tology was limited to the four major histological types,
including papillary, follicular, medullary and anaplastic/
undifferentiated carcinomas and their variants, diagnosed
according to the WHO-classification [4]. Tumours of the
thyroid gland recorded as other carcinomas, metastatic or
recurrent disease, malignant carcinoid, lymphomas or
mesenchymal malignant tumours were excluded from the
current review. Over the observation period from 1983 to
1999, a total of 482 autopsies were performed in Luxem-
bourg. None of these necropsies showed a suspected or
incidental thyroid cancer.
Data on 5,611 surgical specimens resected by 41 senior
surgeons in the nine hospitals of the country during the
period 1990 to 1999 were evaluated. 5,301 thyroidec-
tomy specimens showed benign lesions (i.e. solitary ade-
nomas, parenchymatous diffuse or nodous goiter,
Hashimoto's thyroditis, Graves' disease). 310 specimens
were associated with a suspected or incidental thyroid car-
cinoma and allowed an interpretation in relation to
tumour size, the local and regional spread, the lymph
node and residual tumour status (R). They were analysed
with respect to the TNM-system (i.e.: T: extent of primary
tumour; N: regional lymph node metastasis; M: distant
metastasis; R: residual tumour), according to the guide-
lines of the Union Internationale Contre le Cancer
(UICC) and the American Joint Committee on Cancer
(AJCC) [5,6]. The R-classification of the TNM-system was
performed by conventional methods. In our series the his-
tological examination of the nearest resection margin and
the organ capsule was mandatory. R0 indicates no resid-
ual tumour; R1 corresponds to microscopically and R2 to
macroscopically residual tumour, while Rx did not allow
a statement on residual tumour.
Beside the evaluation of the frequency of the TCs by the 17
'classic' 5-year age categories (0–4 years to 80 years and
above), the changes in incidence of thyroid carcinomas in
relation to four cohorts of patients grouped in youngest
(<20 years of age), younger (20–44 years), middle aged
(45–69 years) and elderly (70 years and above) patients
were reviewed.
The age-standardized (world population) incidence rates
of TCs, diagnosed in the Grand-Duchy of Luxembourg
during the period 1983–1997, were compared with the
data of other geographical European regions with similar
population density and socio-economic characteristics,
published by the WHO in "Cancer in Five Continents",
volumes VI, VII, VIII [7-11].
The observed 3-, 5- and 10-year survival rates of patients
with TC were measured from the time of histopathologic
diagnosis and calculated by the actuarial method (life-
table) with a 95% confidence interval (c.i.). To determine
the sample size for calculating the 95% c.i., the formula n
× p × (1-p) ≥ 9 (n = number of considered patients, p =
survival rate) was used. As the mortality tables of the Lux-
embourgish population in the late 1990s were not yet
available, the relative 5-year survival rate from the period
1990–1994 could only be analysed.
The statistical evaluations included the chi-square test
(χ2) with a level of significance p < 0.05 and the life-tableBMC Cancer 2006, 6:102 http://www.biomedcentral.com/1471-2407/6/102
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survival analysis. The age-standardized incidence rates
were calculated by the direct method, the standard error of
the age-standardized rates by the Poisson approximation
[12].
The fact that data sets on TC from different time periods
were used [i.e. age-standardized (world population) inci-
dence rates over the period 1983–1997 and crude inci-
dence rates, age distribution, tumour sizes, histological
subtypes or observed survival rates from 1990 to 1999]
did not give rise to potential biases.
The files of the tumour registry (MTR) were also reviewed
to detect the percentage of other malignant primaries
developed in patients after an earlier TC. In Luxembourg,
there is neither a systematic screening programme for
early detection of TC nor an adequate programme of
iodine supplementation.
Results
During the period, 1990–1999, the histological diagnoses
of 317 consecutive thyroid cancers removed by surgery
were reviewed. A total of 5,611 surgical specimens
resected for benign or malignant disease of the thyroid
gland concerning 1,114 males and 4,497 females (M/F-
ratio: 1:4) were examined. Seven malignancies in the thy-
roid gland were excluded (3 sarcomas, 2 Non-Hodgkin-
lymphomas, 1 malignant plasmocytoma and 1 metastasis
of a clear cell renal carcinoma). 111 of the 310 patients
with TC were treated by lobectomy of the right thyroid
lobe and 83 of the left lobe, 106 patients had total thy-
roidectomy. For 10 patients there was no precise clinical
Time trend of the age-standardized (world population) incidence rates of thyroid carcinomas (n = 310) by gender; 1990–1999 Figure 1
Time trend of the age-standardized (world population) incidence rates of thyroid carcinomas (n = 310) by gender; 1990–1999.
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site description. The 310 thyroid carcinomas included
248 (80.0%) papillary, 45 (14.5%) follicular, 11 (3.5%)
medullary and 6 (2.0%) anaplastic/undifferentiated carci-
nomas. The 310 carcinomas of the thyroid gland involved
74 males (23.9%) and 236 females (76.1%); M/F-ratio of
1:3.2. The mean age was 48.3 years (range: 13–92). 71 TCs
(22.9%) had a multifocal growth pattern. 140 TCs were
localized in the right thyroid lobe, 106 TCs in the left lobe
and 54 TCs on both sides.
In the follow-up 11.6% of the 310 patients with primary
TC developed a second primary malignant neoplasm in
other organs. 33 out of the 236 female patients with TC
had a subsequent second primary malignant neoplasm,
16 (7.1%) of these were breast cancers, whereas only 3
males out of 74 patients with TC suffered from a second
primary carcinoma (larynx, kidney, urinary bladder).
The average, annual, age-specific rate of thyroid carcino-
mas in Luxembourg over the period 1990–1999 for all
ages and both genders was 7.4 per 100,000: for males 3.6
per 100,000 and for females 11.3 per 100,000. The com-
parison of the crude incidence rates of the patients with
TC diagnosed in the two 5-year periods 1990–1994 and
1995–1999 revealed an increase of 36.5% for both gen-
ders combined from 6.3 to 8.6 per 100,000, for females by
32.0% from 9.7 to 12.8 per 100,000 and for males by
51.7% from 2.9 to 4.4 per 100,000. Comparing the three
3-year time periods from 1990 to 1998 the overall crude
incidence rates of TC in the two first periods, 1990–1992
and 1993–1995, remained stable at 6.3 per 100,000 and
6.0 per 100,000 respectively. In the third period, 1996–
1998, there was a significant increase of the crude inci-
dence rate of TC by 53.3%, from 6.0 per 100,000 to 9.2
per 100,000 (p < 0.05). Additional file 1 displays the
Number of TCs stratified by histological type and tumour size; n = 310 cases; period 1990–1999 Figure 2
Number of TCs stratified by histological type and tumour size; n = 310 cases; period 1990–1999.
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crude incidence rates of TCs (n = 310 cases) for both gen-
ders in relation to the histological subtypes and the
tumour sizes over the study period.
The average, annual, age-standardized incidence rate
(ASR-world population) of thyroid carcinomas during the
study period 1990–1999 was 5.9 per 100,000 for both
genders: for males 3.0 per 100,000 and for females 8.8 per
100,000 (Figure 1). In Additional file 2 the world age-
standardized incidence rates (ASR/W) of TCs in the Lux-
embourgish population (females and males) over the
period 1983–1997 in comparison to other Western Euro-
pean countries, the USA and Canada are presented [7-11].
The total number of TCs rose from 31 cases in 1990 to 45
in 1999 (in females from 24 to 31, in males from 7 to 14).
Comparing the two 5-year periods 1990–1994 to 1995–
1999, there was a significant increase in the absolute
number of all TCs from 126 to 184 cases (p < 0.001). The
absolute number of TCs increased significantly in females
over the two periods from 98 to 138 cases (p < 0.01), in
males from 28 to 46 cases (p < 0.001). In 1997, there was
an abnormal two-fold increase of the number of morpho-
logically confirmed TCs especially in middle-aged
females, which required further investigations focusing
on tumour sizes and the number of surgical treatments.
In our series 124 microcarcinomas – i.e. occult, small TCs
with less than 1 cm in diameter – could be identified. 92
of these were of papillary type, 23 of papillary type variant
follicular, 6 of follicular type and 3 of medullary type (Fig-
ure 2). Time trends of variations in tumour sizes (millime-
Crude incidence rates of invasive thyroid carcinomas and the surgical specimens for benign or malignant diseases for both gen- ders, period: 1990–1999 Figure 3
Crude incidence rates of invasive thyroid carcinomas and the surgical specimens for benign or malignant diseases for both gen-
ders, period: 1990–1999.
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Age-distribution of the thyroid carcinomas (n = 310 cases); 1990–1999 Figure 4
Age-distribution of the thyroid carcinomas (n = 310 cases); 1990–1999.
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tres) are shown in Additional file 1. Indeed, in 1997 out
of 49 TCs, 26 cases (53.1%) were microcarcinomas. This
means a statistically significant 2.4-fold increase, in com-
parison to the average number of microcarcinomas diag-
nosed over the study period.
During the same time (1990–1999) the number of surgi-
cal specimens examined (n = 5,611 cases) remained sta-
ble, 532 specimens in 1990 and 531 in 1999. In Figure 3
the annual crude incidence rates of TC and the annual
crude incidence rates of the surgical specimens are repre-
sented.
The age-distribution of the 310 patients with TC is docu-
mented in Figure 4. In our series only 3 patients (1%)
were children or adolescents, whereas 126 patients
Table 1: Overall observed 3-, 5- and 10-year survival rates of TCs for both genders in relation to the 4 age cohorts (<20 years, 20–44 
years, 45–69 years and >69 years of age) and the 4 histological types (papillary, follicular, medullary and anaplastic carcinomas); n = 310 
cases; period 1990–1999.
1990–1994
Papillary carcinomas Follicular carcinomas Medullary carcinomas Anaplastic carcinomas
3  y 5  y1 0  y3  y 5  y1 0  y3  y 5  y1 0  y3  y 5  y1 0  y
<20 
years
(0/0) (0/0) (0/0) (0/0) (0/0) (0/0) (0/0) (0/0) (0/0) (0/0) (0/0) (0/0)
20–44 y. 100% 
(42/42)
100% 
(42/42)
97.6%* 
(41/42)
100% 
(9/9)
100% 
(9/9)
88.9%* 
(8/9)
(0/0) (0/0) (0/0) (0/0) (0/0) (0/0)
45–69 y. 91.8%* 
(45/49)
89.8%* 
(44/49)
87.8%* 
(43/49)
90.9%* 
(10/11)
90.9%* 
(10/11)
81.8%* 
(9/11)
66.7%* 
(2/3)
66.7%* 
(2/3)
66.7%* 
(2/3)
(0/0) (0/0) (0/0)
>69 
years
66.7%* 
(2/3)
33.3%* 
(1/3)
0% 
(0/3)
57.1%* 
(4/7)
42.9%* 
(3/7)
42.9%* 
(3/7)
100% 
(1/1)
100% 
(1/1)
100% 
(1/1)
0% 
(0/1)
0% 
(0/1)
0% 
(0/1)
1995–1999
Papillary carcinomas Follicular carcinomas medullary carcinomas Anaplastic carcinomas
3 y 5 y 10 y** 3 y 5 y 10 y** 3 y 5 y 10 y** 3 y 5 y 10 y**
<20 
years
100% 
(3/3)
100% 
(3/3)
- (0/0) (0/0) - (0/0) (0/0) - (0/0) (0/0) -
20–44 y. 100% 
(65/65)
100% 
(65/65)
- 100% 
(7/7)
100% 
(7/7)
- 100% 
(3/3)
100% 
(3/3)
-( 0 / 0 ) ( 0 / 0 )-
45–69 y. 98.7%* 
(76/77)
98.7%* 
(76/77)
- 100% 
(9/9)
100% 
(9/9)
- 100% 
(4/4)
100% 
(4/4)
- 0% 
(0/2)
0% 
(0/2)
-
>69 
years
88.9%* 
(8/9)
77.8%* 
(7/9)
- 50%* 
(1/2)
50%* 
(1/2)
- (0/0) (0/0) - 0% 
(0/3)
0% 
(0/3)
-
1990–1999
Papillary carcinomas Follicular carcinomas medullary carcinomas Anaplastic carcinomas
3 y 5 y 10 y** 3 y 5 y 10 y** 3 y 5 y 10 y** 3 y 5 y 10 y**
<20 
years
100% 
(3/3)
100% 
(3/3)
- (0/0) (0/0) - (0/0) (0/0) - (0/0) (0/0) -
20–44 y. 100% 
(107/
107)
100% 
(107/
107)
- 100% 
(16/16)
100% 
(16/16)
- 100% 
(3/3)
100% 
(3/3)
-( 0 / 0 ) ( 0 / 0 )-
45–69 y. 96.0%* 
(121/
126)
95.2%* 
(120/
126)
- 95.0%* 
(19/20)
95%* 
(19/20)
- 85.7%* 
(6/7)
85.7%* 
(6/7)
- 0% 
(0/2)
0% 
(0/2)
-
>69 
years
83.3%* 
(10/12)
66.7%* 
(8/12)
- 55.6%* 
(5/9)
44.4%* 
(4/9)
- 100% 
(1/1)
100% 
(1/1)
- 0% 
(0/4)
0% 
(0/4)
-
* sample size too small for calculating the 95% confidence interval
** data not yet availableBMC Cancer 2006, 6:102 http://www.biomedcentral.com/1471-2407/6/102
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(40.6%; 98 females/28 males) were between 20 and 44
years old, 155 patients (50.0%; 115 females/40 males)
between 45 and 69 years and 26 patients (8.4%; 22
females/4 males) 70 years of age and above.
The overall observed survival rates of the 310 patients
with TC, diagnosed on surgical resection specimens
between 1990 and 1999, were calculated and stratified by
years: 1-year: 95.2+/-2% (n = 295/310); 2-year: 95.2+/-
2% (n = 295/310); 3-year: 93.9+/-3% (n = 291/310); 4-
year: 93.2+/-3% (n = 289/310) and 5-year:92.9+/-3% (n =
288/310). The overall observed 3-year survival rate of the
310 patients with TC was 93.9+/-3% (291/310) and the 5-
year observed survival rate 92.9+/-3% (288/310).
Over the first study period, 1990–1994, the relative 3-year
survival rate of the 126 patients with TC was 93.9+/-4%
for both genders (females: 95.5+/-4%; males: 88.2%), the
relative 5-year survival rate 94.2+/-4% for both genders
(females 95.4+/-4%; males: 90.1%).
In Table 1 the observed 3-, 5- and 10- year survival rates of
TC for both genders in relation to the four histopatholog-
ical types – papillary, follicular, medullary and anaplastic/
undifferentiated carcinomas – and the four cohorts <20
years, 20–44 years, 45–69 years and >69 years of age are
documented. All patients with differentiated TC aged 44
years or less had good prognosis and all patients survived
5 years. Additional file 3 shows the observed 3-, 5- and 10-
year survival rates of TC by time periods, gender and his-
tological type.
In Table 2, the observed 5-year survival rate of 253
patients with TC is stratified by tumour size (pT/UICC)
and by surgical resection for cure (R0). 14 patients with
R1- and R2-status after the first thyroid gland lobectomy
got at least one week later total thyroidectomy for cure. 52
patients with TC were classified as Rx-cases because the
thyroid gland was removed in several irregular fragments.
All 6 patients with an anaplastic/undifferentiated TC died
within the first 3 months after the histopathologic diagno-
sis (survival range: 5–86 days).
Discussion
Thyroid cancer incidence rates have increased steadily in
Luxembourg and elsewhere. Over the observation period,
1990–1999, the overall crude incidence rates of thyroid
carcinomas in Luxembourg rose from 6.4 per 100,000
(1990–1994) to 8.6 per 100,000 (1995–1999). A similar
increase of the age-standardized (world population) inci-
dence rates of TC during the three 5-year periods (1983–
87; 1988–92; 1993–97) has also been reported in many
other Western European and overseas countries (Addi-
tional file 2) [2,9-11,13-16]. In our series mainly women
of childbearing age (60%) were at highest risk. At the
same time 7.1% of our female patients with TC developed
a second primary breast cancer. Some authors believe that
sex hormones may play a role in the etiology of these
tumours [17,18]. An early exposure to common risk fac-
tors or genetic susceptibility of certain subpopulations for
both malignancies may be plausible [19]. Adjadj et al.
investigated, in a series of 2,365 women who were treated
for thyroid carcinoma, 48 women (2.0%) with a subse-
quent breast carcinoma. They did not find a relationship
with I-131 treatment and/or external radiotherapy [20].
It is generally accepted that the thyroid gland is highly
sensitive to radiation-induced oncogenesis [1,15,18,21-
23]. It has been demonstrated that exposure to radiation
at moderate or high levels can cause most forms of can-
cer. Leukaemia and cancers of the breast, lung and thy-
roid are particularly sensitive to induction by radiation,
especially at young ages at exposure (i.e. atmospheric
nuclear weapon programmes in the US and former Soviet
Union, atomic bombing in Japan in 1945) [24]. Substan-
tial evidence is also derived from groups exposed for
environmental reasons, radiotherapeutically or occupa-
tionally, i.e. underground hard rock miners who inhaled
radioactive radon gas and its decay products, patients
irradiated therapeutically for head and neck tumours,
medical staff members. The degree of carcinogenic risk
arising from low levels of radiation exposure is more
contentious, but the available evidence points to an
Table 2: Prognoses of differentiated thyroid carcinomas resected 
for cure (R0)- overall observed 5-year survival rates 1990–1999 
stratified by tumour size (253 cases; exclude 6 anaplastic 
carcinomas).
Observed 5-year survival rates R0
pT1 (0.1–0.9 cm) n = 172 cases 97.1%* (168/172)
0.1–0.4 cm n = 52 cases 98.1%* (51/52)
0.5–0.9 cm n = 57 cases 100% (57/57)
1.0–1.4 cm n = 38 cases 97.4%* (37/38)
1.5–1.9 cm n = 25 cases 92.0%* (23/25)
pT2 (2.0–3.9 cm) n = 44 cases 97.7%* (43/44)
2.0–2.9 cm n = 30 cases 100% (30/30)
3.0–3.9 cm n = 14 cases 92.9%* (13/14)
pT3 (= 4 cm) n = 21 cases 85.7%* (18/21)
pT4 (any size, extend 
beyond thyroid capsule)
n = 16 cases 93.8%* (15/16)
* sample size too small for calculating the 95% confidence intervalBMC Cancer 2006, 6:102 http://www.biomedcentral.com/1471-2407/6/102
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increased risk that is approximately proportional to the
dose received [24,25]. In the US radiologic technologists
health study from 1983 to 1998 analysing the cancer
incidence in medical staff exposed to low doses of radia-
tion, an elevated risk for thyroid cancer in both genders
was reported. The observed excesses in this cohort may
also reflect, at least in part, an earlier detection among
medical staff with easy access to health care procedures
[26].
The thyroid gland of children is particularly vulnerable to
the carcinogenic action of ionizing radiation. This may
explain why the incidence of TC in children in the Cher-
nobyl area increased to a peak exceeding 10 per 100,000
in this area after the nuclear accident [1,18,21]. Addition-
ally it has been reported that probably at least some of the
children, who are treated by external fractionated radio-
therapy for cancer, are predisposed to develop a later TC
[25,27]. In contrast to some Eastern European countries,
such as Belarus, Ukraine, Poland, or even Great Britain, we
did not find an increase of childhood thyroid cancers (Fig-
ure 3) [1,22,28]. Only 3 cases of TC in children and ado-
lescents of 20 years of age or less, could be diagnosed in
our series of the 1990s. This does not support the hypoth-
esis of increased radiation-associated TC in Luxembourg
following the exposure to nuclear fallout after the Cherno-
byl accident as a causative effect. This is consistent with
the low individual (mean) dose of radiation following the
accident 20 years ago which the Luxembourgish popula-
tion was exposed to. The dose measured from 1 May 1986
to 1 May 1987 by the radioprotection division staff of the
National Health Directorate (Ministry of Health) and
which did not vary across the country, was 12.2 millirem.
During the same period, the radioactive exposure in the
Netherlands was 6.1 millirem and 21 millirem in Switzer-
land [29]. Similar observations in France were reported by
Verger P et al. [2].
In our study, the large majority of TC (80%) was of the
papillary histopathological subtype, 14.5% were follicu-
lar, 3.5% medullary and 2.0% anaplastic/undifferentiated
carcinomas. Bhattacharyya et al. published 18,118 cases
of differentiated thyroid carcinoma cases from the US Sur-
veillance, Epidemiology and End-Results (SEER) cancer
registry programme database, registered between 1988
and 1998 [30]. These identified cases included 87.3%
papillary, 9.9% follicular and 2.8% medullary carcino-
mas. The differences in the percentage of papillary and fol-
licular carcinomas may be attributable to a more strict
application of the histopathologic WHO-classification in
our department. Indeed, since 1995, we used in particular
the diagnosis of the papillary TC, variant follicular (i.e.
Lindsay tumour) in 55 cases (Figure 2). In the early 1990s
these tumours with so called ground-glass nuclei were
sometimes classified as atypical follicular adenomas when
they were encapsulated or as follicular TC when a capsular
and vascular infiltration could be detected. This changing
diagnostic practice may partially explain the particularly
low percentage of follicular TC in our series in the second
study period. A similar shift in histopathological diag-
noses from follicular to papillary TC has been observed in
Switzerland by Verkooijen et al. [31].
It has been argued that many of the reported TC cases
could correspond to a dormant and thus clinically irrele-
vant type of carcinoma, a so-called occult TC [31-34].
These silent carcinomas were often considered as non-pal-
pable 'microcarcinomas' of less than 1 centimetre of size.
In fact, a large and noticeable proportion of our 310 TCs
were differentiated microcarcinomas including 46.4%
(115/248) papillary TCs, 13.3% (6/45) follicular and
27.3% (3/11) medullary thyroid carcinomas (Additional
file 1, Figure 2). In the literature a comparable increase of
the percentage of microcarcinomas of TCs over the last 30
years, varying between 7% and 16.6%, has been reported
[31,35].
To explain the two-fold increase of the diagnosed TC in
1997 in our series, we reviewed the patient data in our
files and analysed the findings in relation to the patients'
nationalities and the tumour sizes. Luxembourg is a coun-
try with a high immigration rate, 29.4% of the residents
came from abroad (census data 1991, STATEC). Because
only 10 of our 49 patients with TC (20.4%) diagnosed in
1997 were from abroad, a relationship between the TC
increase and the immigration rate is not likely. The analy-
sis of the tumour sizes of TC showed that in 1997, there
was also a two-fold increase of the incidental microcarci-
nomas of the papillary type, which may be the major
cause of the peak in 1997. The number of surgical treat-
ments for enlarged thyroid gland decreased slightly. If we
consider the crude incidence rates for both, TC and surgi-
cal specimens, the findings remained stable over the study
period (Figure 3). Because there is no relationship
between the frequency of microcarcinomas and the abso-
lute number of surgical treatments, it may be that
improved image giving procedures (i.e. ultrasound, com-
puter scanner) play a role in the detection of more suspi-
cious nodular lesions of less than 1 centimetre in greatest
size [36]. The same holds true for a study of 471 cases
from France between 1980 and 2000. There was a rise in
prevalence of TCs among operated patients from 12% to
37%, although the proportion of patients undergoing sur-
gery remained stable [16].
The high percentage of patients with thyroid microcarci-
nomas (<1 cm), particularly of the differentiated papillary
type, may also be one reason for the high survival rates in
our series (Table 2). Thyroid carcinomas generally have
good prognosis, especially in patients of 44 years of age orBMC Cancer 2006, 6:102 http://www.biomedcentral.com/1471-2407/6/102
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less, except for undifferentiated carcinomas (none of our
6 patients survived three months). Long-term follow-up
beyond 10 or 20 years is needed to clearly demonstrate an
excess in mortality as a consequence of the increasing
number of diagnosed TCs. The observed 3-, 5- and 10-year
survival rates (Additional file 1) in relation to the different
histopathological tumour types and the genders demon-
strated a better prognosis in both genders over the two
time periods (1990–1994 and 1995–1999) and decreas-
ing survival rates for papillary TC, followed by follicular,
medullar and anaplastic carcinomas. The prognosis in
general was worse in men than in women. We found 10-
year survival rates between 71.4% and 90.4% (Additional
file 3).These data are in concordance with the findings of
others reporting independent of the histological type, an
overall 10-year survival rate varying between 74.0% and
89.4% [13,21,35,37,38]. The relative survival rates for TC
patients would give better data for TC in Luxembourg
than indicated by the observed survival rates reported
here.
Conclusion
The increasing thyroid cancer incidence rates especially of
the papillary subtype seem mainly due to the increase in
the diagnosed microcarcinomas over the last 5 years due
to some extent to changes in histological diagnostic crite-
ria (i.e. atypical follicular adenoma with so-called ground-
glass nuclei being classified now as papillary TC follicular
variant). Particularly female patients at childbearing age
were concerned. The number of thyroid surgery over the
study period remaining stable, the increase of incidentally
discovered TC cases may also be linked to the use of more
efficient diagnostic tools. Changes in immigration rates
had no influence on the number of diagnosed TCs and
neither did the Chernobyl fallout since no rise in the
number of childhood cancers was found. Survival rates in
males and the elderly were worse than in women and
younger patients. The prognosis of undifferentiated thy-
roid cancers was extremely poor.
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